Year archive

TransThera Sciences (Nanjing), Inc. — 2026 filings

All 31 regulatory filings released by TransThera Sciences (Nanjing), Inc. (2617) in 2026, sourced directly from the official regulator.

31 Filings

2026 Period

2026 filings (31)

Filing	Released	Lang
RULES RELATING TO THE 2026 H SHARE AWARD SCHEME Governance Information	2026-05-22	English
FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON 18 JUNE 2026 OR ANY ADJOURNMENT THEREOF Proxy Solicitation & Information Statement	2026-05-22	English
NOTICE OF THE EXTRAORDINARY GENERAL MEETING Proxy Solicitation & Information Statement	2026-05-22	English
(1) PROPOSED ADOPTION OF THE H SHARE AWARD SCHEME (2) PROPOSED AUTHORIZATION TO THE SCHEME ADMINISTRATOR TO DEAL WITH MATTERS RELATED TO THE H SHARE AWARD SCHEME AND (3) NOTICE OF THE EGM Proxy Solicitation & Information Statement	2026-05-22	English
PLACING OF NEW H SHARES UNDER GENERAL MANDATE Regulatory Filings	2026-05-19	English
VOLUNTARY ANNOUNCEMENT TransThera Sciences (Nanjing) Publishes Clinical Results of Tinengotinib as Monotherapy and in Combination with Atezolizumab for Advanced Solid Tumors on Nature Communications Regulatory Filings	2026-05-17	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026 (Re-submission) Regulatory Filings	2026-05-06	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026 Regulatory Filings	2026-05-06	English
ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2025 Environmental & Social Information	2026-04-23	English
ANNUAL REPORT 2025 Annual Report FY 2025	2026-04-23	English
Next Day Disclosure Return Transaction in Own Shares	2026-04-21	English
COMPLETION OF PLACING OF NEW H SHARES UNDER THE GENERAL MANDATE Capital/Financing Update	2026-04-21	English
VOLUNTARY ANNOUNCEMENT TransThera Sciences (Nanjing), Inc. Presented Lineage Reprogramming as a Resistance Mechanism to Endocrine Therapy in HR+ Breast Cancer, as Well as Preclinical Data for Tiangoti Regulatory Filings	2026-04-21	English
VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED IN CONFIRMATORY PHASE III CLINICAL TRIAL OF TINENGOTINIB MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH ADVANCED CHOLANGIOCARCINOMA Regulatory Filings	2026-04-17	English
PLACING OF NEW H SHARES UNDER GENERAL MANDATE Share Issue/Capital Change	2026-04-15	English
PROPOSED ADOPTION OF THE H SHARE AWARD SCHEME Regulatory Filings	2026-04-07	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026 Regulatory Filings	2026-04-02	English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS Board/Management Information	2026-03-31	English
CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND RESIGNATION OF NON-EXECUTIVE DIRECTOR Board/Management Information	2026-03-31	English
DISSOLUTION OF THE SUPERVISORY COMMITTEE AND PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION, THE RULES OF PROCEDURE OF SHAREHOLDERS' GENERAL MEETINGS AND THE RULES OF PROCEDURE OF THE BOARD OF DIR Governance Information	2026-03-31	English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025 Annual Report FY 2025	2026-03-31	English
DATE OF BOARD MEETING Report Publication Announcement	2026-03-19	English
VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED IN PHASE II CLINICAL TRIAL OF TINENGOTINIB IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF PREVIOUSLY TREATED HR+/HER2 - RELAPSED OR METASTATIC BREAST C Regulatory Filings	2026-03-18	English
VOLUNTARY ANNOUNCEMENT INCLUSION OF THE COMPANY AS A CONSTITUENT OF THE HANG SENG INDEX SERIES Regulatory Filings	2026-03-09	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2026 Regulatory Filings	2026-03-03	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2026 Share Issue/Capital Change	2026-02-04	English
Next Day Disclosure Return Share Issue/Capital Change	2026-01-20	English
COMPLETION OF PLACING OF NEW H SHARES UNDER THE GENERAL MANDATE Share Issue/Capital Change	2026-01-20	English
PLACING OF NEW H SHARES UNDER GENERAL MANDATE Capital/Financing Update	2026-01-13	English
VOLUNTARY ANNOUNCEMENT PRESENTATION OF CLINICAL DATA ANALYSIS OF TINENGOTINIB MONOTHERAPY IN PATIENTS WITH ADVANCED CHOLANGIOCARCINOMA AT 2026 ASCO GI Regulatory Filings	2026-01-12	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025 Regulatory Filings	2026-01-05	English